Cellbox Solutions Completes Series A Funding Round Totaling 5 Million Euros
The Next Phase of the Company's Development Begins
Advertisement
Cellbox Solutions, a technology company specializing in warm-chain logistics, has successfully completed its Series A funding round with a total volume of 5 million euros. With the additional capital, the company is driving the further development of its business model and expanding its offerings to include integrated logistics solutions for cells, tissues, organoids, and other sensitive biological materials.
The funding lays the foundation for the next phase of commercial growth and builds on the technological, product-related, and regulatory advances Cellbox Solutions has achieved in recent years. The focus is on expanding the existing logistics offering: In the future, controlled transport under physiological conditions will be even more closely integrated with complementary logistics and services.
After Cellbox Solutions had already secured an initial round of funding totaling approximately 3.5 million euros in March 2026, the company was able to attract additional investors for this financing round. These include members of Baltic Business Angels Invest GmbH, a Canadian family office, and an unnamed investor with extensive experience in pharmaceutical logistics. In addition, existing investors NRW.BANK and Fraunhofer Venture participated in the financing once again. The first closing of the financing round was led by Companisto.
Cellbox™ Go and Cellbox™ Shipper form the technological foundation for the further expansion of the business model. Both incubators enable controlled transport under defined temperature and CO₂ conditions by land and air and are already being used internationally in research and in cell therapy applications.
With over 400 Cellbox™ incubators on the market, a growing customer base, and a regulatory framework that includes Drug Master Files for the Cellbox™ product family, the company is well-positioned to expand its commercial offerings. The Cellbox™ systems are combined with rental and transportation services as well as recurring services such as monitoring, fleet management, and shipping coordination. This approach is intended to provide customers with even more flexible and comprehensive support for their logistics processes in the future.
“In recent years, we have laid a solid foundation for the controlled transport of live biological materials,” said Prof. Dr. Kathrin Adlkofer, founder and CEO of Cellbox Solutions. “With the completion of our Series A funding round, we are now expanding our established warm-chain technology platform into a broader offering for physiological logistics. This will enable us to support our customers even more comprehensively throughout their logistics processes while simultaneously expanding our presence in key international markets.”
In the long term, Cellbox Solutions aims to establish physiological logistics as a scalable approach for transporting biological materials that require controlled environmental conditions. To this end, the company is further expanding its activities in Europe, Asia, and North America and is increasingly focusing on strategic partnerships with logistics service providers.
“The completion of the Series A funding round provides us with additional capital to further develop the business model centered on our technologies. We are expanding our range of rental and recurring services and integrating them with transportation, monitoring, and complementary logistics services. This enables us to build long-term customer relationships and establish our scalable service model in multiple markets. Our focus is now on translating the strengths of the Cellbox™ platform into sustainable growth,” explained Dr. Bernd Muehlenweg, CBO & CFO at Cellbox Solutions.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.